Table 3 Safety of remdesivir in human clinical trials

Discontinued rate (Remdesivir) 10-day

9.8%

11.6%

7.5%

10.2%

4.1%

Discontinued rate (Remdesivir) 5-day

4.5%

2.1%

Discontinued rate (Control) 10-day

13.5%

5.1%

Discontinued rate (Remdesivir/control)

0.73

2.27

2.27^f

Serious adverse events (Remdesivir-10 day)

24.6%

18.1%

22.6%

34.5%

5.2%

Serious adverse events (Remdesivir-5 day)

21.0%

4.7%

Serious adverse events (Control)

31.6%

25.6%

9.0%

Adverse events (Remdesivir/control)

0.78

0.69

1.64

Death (Remdesivir-10 day)

10.9%

14.2%

13.2%

10.7%

1.6%

Death (Remdesivir-5 day)

8.0% 

1.0%

Death (Control)

14.8%

12.8%

2.0%